Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019.
Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.
Several networking opportunities are still available to investors or delegates of other companies that may wish to meet the Genprex team one-on-one. Those interested in setting a meeting are asked to contact the company at [email protected].
Genprex will present at the Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum as follows:
Date: Friday, May 31, 2019
Time: 11:10 a.m. CT
Venue: Waldorf Astoria Chicago
Room: Sinclair Ballroom
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the company’s presentation and will be available for one-on-one meetings.